Abstracts Archive - Page 2377 of 2607 - ACR Meeting Abstracts

Abstract Number: 814 • 2013 ACR/ARHP Annual Meeting
Results Of a Randomised Controlled Trial Comparing Tight Control Of Early Psoriatic Arthritis (TICOPA) With Standard Care: Tight Control Improves Outcome
Laura C. Coates^1,2, Anna R. Moverley^1,2, Lucy McParland³, Sarah Brown³, Howard Collier³, Jennifer Law³, Sarah R. Brown³, Neil Corrigan³, Nuria Navarro-Coy^3,4, Paul Emery^2,5, Philip G. Conaghan^1,2 and Philip S. Helliwell^1,6, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: The aim of this study was to assess the impact of tight control of early psoriatic arthritis (PsA) in a randomised-controlled trial (RCT) using…
Abstract Number: 815 • 2013 ACR/ARHP Annual Meeting
Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis (PALACE 2)
Maurizio Cutolo¹, Gary E. Myerson², Roy Fleischmann³, Frédéric Lioté⁴, Federico Díaz-González⁵, Filip Van den Bosch⁶, Helena Marzo-Ortega⁷, Eugen Feist⁸, Kamal Shah⁹, ChiaChi Hu⁹, Randall M. Stevens⁹ and Airi Poder¹⁰, ¹University of Genova, Genova, Italy, ²Arthritis and Rheumatology of Georgia, Atlanta, GA, ³Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Hôpital Universitaire Lariboisière, Paris, France, ⁵Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Leeds Musculoskeletal Biomedical Research Unit and University of Leeds, Leeds, United Kingdom, ⁸Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁹Celgene Corporation, Warren, NJ, ¹⁰Clinical Research Centre Ltd, Tartu, Estonia
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. PALACE 2 compared the efficacy and safety of APR…
Abstract Number: 816 • 2013 ACR/ARHP Annual Meeting
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvements In Enthesitis and Dactylitis In Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials
Dafna D. Gladman¹, Philip J. Mease², Arthur Kavanaugh³, Adewale O. Adebajo⁴, Juan J. Gomez-Reino⁵, Jürgen Wollenhaupt⁶, Maurizio Cutolo⁷, Georg Schett⁸, Eric Lespessailles⁹, Kamal Shah¹⁰, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³University of California San Diego, San Diego, CA, ⁴Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁵Hospital Clinico Universitario, Santiago, Spain, ⁶Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁷University of Genova, Genova, Italy, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹University of Southampton, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…
Abstract Number: 817 • 2013 ACR/ARHP Annual Meeting
Clinical Response To Brodalumab, An Anti-Interleukin-17 Receptor Antibody, In Subjects With Psoriatic Arthritis
MC Genovese¹, Philip J. Mease², Maria W. Greenwald³, Christopher T. Ritchlin⁴, André Beaulieu⁵, Atul A. Deodhar⁶, Richard Newmark⁷, JingYuan Feng⁸, Ngozi Erondu⁸ and Ajay Nirula⁸, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Desert Medical Advances, Palm Desert, CA, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Faculty of Medicine, Laval University, Quebec, QC, Canada, ⁶Oregon Health and Science University, Portland, OR, ⁷Clinical Development, Amgen Inc, Thousand Oaks, CA, ⁸Amgen Inc, Thousand Oaks, CA
Background/Purpose: Psoriasis-associated skin and joint disorders are characterized by ongoing inflammation mediated by similar molecular pathways. IL-17 plays a potential role in the pathogenesis and…
Abstract Number: 818 • 2013 ACR/ARHP Annual Meeting
HLA-B*0801 Is Strongly Associated With Asymmetrical Sacroiliitis and HLA-B*27 With Symmetrical Involvement In Psoriatic Arthritis: Results Of a Long-Term Follow-Up Study Examining Clinical and Genetic Predictors Of Radiographic Sacroiliitis
Muhammad Haroon¹, Agnes Szentpetery², Phil Gallagher³, Robert Winchester⁴ and Oliver FitzGerald¹, ¹Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Dept of Medicine & Pathology, Columbia University, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is characterised by involvement of both the appendicular and axial skeleton. Little is known about the clinical predictors of sacroiliitis (SI),…
Abstract Number: 819 • 2013 ACR/ARHP Annual Meeting
Low Diagnostic Utility Of Candidate Definitions For a Positive MRI Of The Spine In Axial Spondyloarthritis
Ulrich Weber¹, Veronika Zubler², Zheng Zhao³, Robert GW Lambert⁴, Kaspar Rufibach⁵, Stanley Chan⁶, Susanne Juhl Pedersen⁷, Mikkel Ostergaard⁸ and Walter P. Maksymowych⁹, ¹Rheumatology, Balgrist University Hospital, Zurich, Switzerland, ²Radiology, Balgrist University Hospital, Zurich, Switzerland, ³Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, ⁴Radiology, University of Alberta, Edmonton, AB, Canada, ⁵rePROstat, Basel, Switzerland, ⁶Division of Ophthalmology, University of Alberta, Edmonton, AB, Canada, ⁷Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁸Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁹Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: A recent consensus statement based on a systematic literature review by the Assessment of SpondyloArthritis International Society suggested the presence of ≥3 corner inflammatory…
Abstract Number: 820 • 2013 ACR/ARHP Annual Meeting
CC-220: A Clinical Stage Immunomodulatory, Antifibrotic Drug For Systemic Sclerosis
Jörg HW Distler¹, Yongqing Wang², Pawel Zerr³, Katrin Palumbo⁴, Gerald Horan⁵, Peter Schafer⁵ and Bashar Kahaleh⁶, ¹Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Medicine, University of Toledo, Toledo, OH, ³Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Translational Development, Celgene Corporation, Summit, NJ, ⁶Medicine/Rheumatology, University of Toledo, Toledo, OH
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune fibrotic disease in which B cells may play a crucial role in pathogenesis. CC-220 is an immunomodulatory drug…
Abstract Number: 821 • 2013 ACR/ARHP Annual Meeting
Activation Of The Signal Transducer and Activator Of Transcription 3 By Transforming Growth Factor-Beta Promotes Fibroblast Activation and Tissue Fibrosis
Barbora Sumova^1,2, Katrin Palumbo-Zerr³, Clara Dees³, Pawel Zerr³, Oliver Distler⁴, Georg Schett⁵, Ladislav Senolt⁶ and Joerg H. W. Distler³, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Germany, Erlangen, Germany, ²Department of Rheumatology of the First Faculty of Medicine, Institute of Rheumatology and Connective Tissue Research Laboratory, Prague, Czech Republic, ³Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic sclerosis (SSc) is characterized by uncontrolled activation of fibroblasts resulting in tissue fibrosis in which the TGFβ signaling plays a main role. Signal…
Abstract Number: 822 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis
Yun Zhang, Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Casein kinase-2 (CK2) is a highly conserved serine/threonine kinase. CK2 is a tetramer composed of 2 catalytic subunits (α or α’) and 2 β…
Abstract Number: 823 • 2013 ACR/ARHP Annual Meeting
Activation Of Liver X Receptors Inhibits Experimental Fibrosis By Interfering With Interleukin-6 Release From Macrophages
Christian Beyer¹, Jürgen Beer¹, Katrin Palumbo-Zerr¹, Pawel Zerr¹, Alfiya Distler¹, Clara Dees¹, Louis E. Munoz¹, Gerhard Krönke¹, Oliver Distler², Steve Anderson³, Georg A. Schett⁴ and Joerg H. W. Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Lexicon Pharmaceuticals Inc., The Woodlands, TX, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Liver X receptors (LXRs) are orphan nuclear receptors with emerging roles in metabolic and autoimmune diseases. Here, we investigated the role of LXRs in…
Abstract Number: 824 • 2013 ACR/ARHP Annual Meeting
Bosentan Improves Vascular Abnormalities In Endothelial Cell-Specific Fli1 Knockout Mice By Increasing The DNA Binding Ability Of Fli1 – a Possible Mechanism Explaining The Effect Of Bosentan On Scleroderma Vasculopathy
Kaname Akamata¹, Yoshihide Asano¹, Takashi Taniguchi¹, Takehiro Takahashi¹, Yohei Ichimura¹, Tetsuo Toyama¹, Maria Trojanowska² and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Arthritis Center, Boston University, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by initial vascular injuries and resultant fibrosis of skin and certain internal organs. Although there…
Abstract Number: 825 • 2013 ACR/ARHP Annual Meeting
Activating Transcription Factor 3 Regulates Canonical Transforming Growth Factor Beta Signaling In Experimental Fibrosis
Tatjana Mallano¹, Katrin Palumbo-Zerr¹, Christian Beyer¹, Clara Dees¹, Jingang Huang¹, Tsonwin Hai², Georg A. Schett³ and Joerg H. W. Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²The Ohio State Biochemistry Program, The Ohio State University, Columbus, USA, Colombus, OH, ³Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Activating transcription factor 3 (ATF3), a member of the activating transcription factor/cAMP-responsive element binding protein (ATF/CREB) family of transcription factors is induced by various…
Abstract Number: 826 • 2013 ACR/ARHP Annual Meeting
The Value Of History and Physical Examination Findings In The Diagnosis Of Symptomatic Meniscal Tear Among Middle-Age Subjects With Knee Pain
Jeffrey N. Katz¹, Yan Dong², John Wright³, Stephanie Chen⁴, Scott Martin⁵, Laurel Donnell-Fink⁵, Benjamin N. Rome² and Elena Losina², ¹Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ²Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ³Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, ⁴Orthopedics and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Clinicians often rely on mechanical symptoms (e.g. clicking, catching, popping, giving way) and tests such as the McMurray sign in the diagnosis of symptomatic…
Abstract Number: 827 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness and Cost-Utility Of a One-Year Coaching Program For Healthy Physical Activity In Rheumatoid Arthritis
Nina Brodin^1,2, Malin Lohela Karlsson³, Emma Swärdh² and Christina H. Opava⁴, ¹Department of Orthopaedics, Division of Physiotherapy, Dandeyd Hospital, Stockholm, Sweden, ²Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, SE 14183 Huddinge, Sweden, ³Institute of Environmental Medicine (IMM), Intervention and Implementation Research Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Neurobiology, Care Sciences and Society, Division of Physical Therapy, Karolinska Institutet, Huddinge, Sweden
Background/Purpose: Economic evaluations of interventions, as a complement to the effect evaluation, intend to inform decision makers about whether an intervention provides good value for…
Abstract Number: 788 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tocilizumab In Refractory Adult-Onset Still’s Disease: Multicenter Study Of 32 Patients
Francisco Ortiz-Sanjuan¹, Ricardo Blanco², Javier Narvaez³, Esteban Rubio Romero⁴, Alejandro Olivé⁵, Santos Castañeda⁶, Adela Gallego Flores⁷, M. Victoria Hernández⁸, Cristina Mata¹, Inmaculada Ros Vilamajo⁹, Alberto Sifuentes Giraldo¹⁰, M Caracuel¹¹, Mercedes Freire¹², Catalina Gómez Arango¹³, José Llobet¹⁴, Sara Manrique Arija¹⁵, Carlos Marras¹⁶, Concepcion Moll Tuduri¹⁷, Chamaida Plasencia Rodriguez¹⁸, Rosa Roselló¹⁹, Ana Urruticoechea²⁰, Maria Luisa Velloso Feijoo²¹, Javier Loricera¹, Vanesa Calvo-Rio¹ and Miguel A González-Gay²², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Hospital Marques de Valdecilla, Santander, Spain, ³Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, ⁵Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁶Rheumatology, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, ⁷Rheumatology, Hospital de Mérida, Mérida, Spain, ⁸Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ⁹Hospital Son Llàtzer, Palma de Mallorca, Spain, ¹⁰Rheumatology, H Ramón y Cajal, Madrid, Spain, ¹¹Rheumatology., Hospital de Córdoba., Córdoba, Spain, ¹²Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹³HU Basurto, Bilbao, Spain, ¹⁴H Sant Pau, Barcelona, Spain, ¹⁵HRU Carlos Haya, Málaga, Spain, ¹⁶Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ¹⁷Hospital Mateu Orfila. Menorca. Spain, Mahón (Menorca), Spain, ¹⁸HU La Paz, Madrid, Spain, ¹⁹H San Jorge, Huesca, Spain, ²⁰Hospital Can Misses, Ibiza, Spain, ²¹H Valme, Sevilla, Spain, ²²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Adult-onset Still's disease (AOSD) is frequently refractory to standard immunosuppressive drugs and it may require biological therapy. Tocilizumab (TCZ) has demonstrated efficacy in clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].